A retatrutidea new triple hormone receptor agonist (GIP, GLP-1 and glucagon), demonstrated significant efficacy in weight loss in adults with type 2 diabetes.
The study TRANSCEND-T2D-1carried out in 48 medical centers in the United States, Mexico and Indiafollowed 537 participants for 40 weeks.
Study results
The data reveal that weekly use of 12 mg of the drug promoted an average reduction of 15.3% no body weightwhile the placebo group recorded only a 2.6% decrease. In analyzes of maximum effectiveness, the loss reached 17% at the highest dose.
In addition to weight loss, the drug showed improvements in glycemic control and in cardiometabolic parameters, such as reducing blood pressure and improving the lipid profile.
Safety and tolerability
The most frequent adverse effects were of a gastrointestinalsuch as nausea and diarrhea, mostly classified as mild to moderate.
The study, funded by Eli Lilly, indicates that retatrutide It has the potential to be a first-line therapy in the treatment of early diabetes associated with obesity.
